foscarnet and dichlororibofuranosylbenzimidazole

foscarnet has been researched along with dichlororibofuranosylbenzimidazole in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Breitenbach, JM; Devivar, RV; Drach, JC; Kawashima, E; Kreske, ED; Revankar, GR; Townsend, LB	1
Alain, S; Alexander, BD; Avery, RK; Blumberg, EA; Chemaly, RF; Cordonnier, C; Duarte, RF; Florescu, DF; Fournier, M; Kamar, N; Kumar, D; Maertens, J; Marty, FM; Papanicolaou, GA; Silveira, FP; Sundberg, AK; Witzke, O; Wu, J	1
Blumberg, EA; Halpern-Cohen, V	1

Reviews

1 review(s) available for foscarnet and dichlororibofuranosylbenzimidazole

Article	Year
New Perspectives on Antimicrobial Agents: Maribavir. Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9 Topics: Adult; Anti-Infective Agents; Antiviral Agents; Benzimidazoles; Child; Cidofovir; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Valganciclovir	2022

Trials

1 trial(s) available for foscarnet and dichlororibofuranosylbenzimidazole

Article	Year
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4 Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Valganciclovir; Viremia	2022

Article

Year

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Valganciclovir; Viremia

2022

Other Studies

1 other study(ies) available for foscarnet and dichlororibofuranosylbenzimidazole

Article	Year
Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles. Journal of medicinal chemistry, 1994, Sep-02, Volume: 37, Issue:18 Topics: Antiviral Agents; Cell Line; Cell Survival; Cytomegalovirus; Dichlororibofuranosylbenzimidazole; Drug Design; Fibroblasts; Herpesvirus 1, Human; Humans; KB Cells; Structure-Activity Relationship	1994

Article

Year

Benzimidazole ribonucleosides: design, synthesis, and antiviral activity of certain 2-(alkylthio)- and 2-(benzylthio)-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazoles.

Journal of medicinal chemistry, 1994, Sep-02, Volume: 37, Issue:18

Topics: Antiviral Agents; Cell Line; Cell Survival; Cytomegalovirus; Dichlororibofuranosylbenzimidazole; Drug Design; Fibroblasts; Herpesvirus 1, Human; Humans; KB Cells; Structure-Activity Relationship

1994